Recent developments in CCR2 antagonists

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 3, 2009, Pages 295-303

  Xia, Mingde ^a   Sui, Zhihua ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Asthma; CCR2 antagonist; MCP 1; Multiple sclerosis; Rheumatoid arthritis

Indexed keywords

1H INDOLE 2 CARBOXYLIC ACID N (PIPERIDIN 4 YL)AMIDE; [3 ISOPROPYL 3 [[3 (TRIFLUOROMETHYL) 7,8 DIHYDRO 1,6 NAPHTHYRIDIN 6(5H) YL]CARBONYL]CYCLOPENTYL][3 METHOXYTETRAHYDRO 2H PYRAN 4 YL]AMINE SALT; AMINOPYRROLIDINE DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; BINDARIT; BMS 741672; CCX 140; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; DEXAMETHASONE; DIAMINOPROPIONAMIDE GLYCINE DIPEPTIDE; DIPIPERIDINE DERIVATIVE; GSK 1344386B; INCB 3284; INCB 3344; INCB 8696; INDAZOLE DERIVATIVE; MERCAPTOIMIDAZOLE; MK 0812; N [3,5 BIS(TRIFLUOROMETHYL)BENZYL] 1 METHYL 3 METHYL 11H SPIRO[INDENE 1,44 PIPERIDIN] 11 YL]CYCLOPENTANECARBOXAMIDE; N PIPERIDINYLETHYLCYCLOHEXYL INDOLECARBOXAMIDE DERIVATIVE; NIBR 1282; NIBR 177; PIPERAZINE DERIVATIVE; PIPERIDINYLCARBOXAMIDE DERIVATIVE; PLACEBO; PYRROLIDIN 2 ONE DERIVATIVE; PYRROLIDINE DERIVATIVE; PYRROLIDINYLCARBOXAMIDE DERIVATIVE; QUATERNARY AMMONIUM DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLERGIC ENCEPHALOMYELITIS; ARTHRITIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CHEMOTAXIS; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; GRAFT REJECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; INFLAMMATORY DISEASE; INSULIN RESISTANCE; LUPUS ERYTHEMATOSUS NEPHRITIS; METABOLIC DISORDER; MONOCYTE; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NONHUMAN; RESTENOSIS; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMOKINE CCL2; CHEMOTAXIS; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; INFLAMMATION; MONOCYTES; PATENTS AS TOPIC; RECEPTORS, CCR2;

EID: 67649400529     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770902755129     Document Type: Review

References (42)

1. Tsutsumi C, Sonoda K, Egashira K, et al. The critical role of ocular- infiltrating macrophages in the development of choroidal neovascularization. J Leukoc Biol 2003;74:25-32 (Pubitemid 38040433)
2. Conrad SM, Strauss-Ayali D, Field AE, et al. Leishmania-derived murine monocyte chemoattractant protein 1 enhances the recruitment of a restrictive population of CC chemokine receptor 2-positive macrophages. Infect Immun 2007;75:653-665 (Pubitemid 46203427)
3. Boring L, Gosling J, Cleary M, et al. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394:894-897 (Pubitemid 28410911)
4. Carulli MT, Ong VH, Ponticos M, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 2005;52:3772-3782 (Pubitemid 41798215)
5. Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006;116:115-124 (Pubitemid 43121796)
6. Charo IF, Taubman MB. Chemokines in the pathogenesis of Vascular Disease. Circ Res 2004;95:858-866 (Pubitemid 39435000)
7. Kitagawa K, Wada T, Furuichi K, et al. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 2004;165:237-246 (Pubitemid 38821831)
8. Dawson J, Miltz W, Mir AK, et al. Targeting monocyte chemoattractant protein-1 signalling in disease. Expert Opin Ther Targets 2003;7:35-48 (Pubitemid 36204587)
9. Rollins BJ. Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today 1996;2:198-204 (Pubitemid 126401890)
10. Ogilvie P, Thelen S, Moepps B, et al. Unusual chemokine receptor antagonism involving a mitogen-activated protein kinase pathway. J Immunol 2004;172:6715-6722 (Pubitemid 38669108)
11. Belvisi MG, Hele DJ, Birrell MA. New anti-inflammatory therapies and targets for asthma and chronic obstructive pulmonary disease. Expert Opin Ther Target 2004;8:265-285 (Pubitemid 39117693)
12. Merck.Preparation of [(1R,3S)-3-isopropyl-3-[[3-(trifluoromethyl)-7,8- dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl] cyclopentyl][(3S,4S)-3- methoxytetrahydro-2H-pyran-4-yl]amine salt as chemokine receptor CCR-2 antagonist. WO2005044795; 2005
13. Yang L, Jiao RX, Moyes C, et al. Discovery of 3-piperidinyl-1- cyclopentanecarboxamide as a novel scaffold for highly potent CC chemokine receptor 2 antagonists. J Med Chem 2007;50:2609-2611 (Pubitemid 46896068)
14. Butora G, Jiao R, Parsons WH, et al. 3-Amino-1-alkyl-cyclopentane carboxamides as small molecule antagonists of the human and murine CC chemokine receptor 2. Bioorg Med Chem Lett 2007;17:3636-3641 (Pubitemid 46898824)
15. Janssen. Preparation of mercaptoimidazoles as CCR2 receptor antagonists. WO2005118578; 2005
16. Janssen. Substituted dipiperidines as CCR2 antagonists, their preparation, pharmaceutical compositions, and use in therapy. US2006069123; 2006
17. Janssen. Preparation of quaternary ammonium salts as chemoattractant cytokine receptor 2 antagonists. WO2006012135; 2006
18. Janssen. Substituted cyclopentyl piperidine CCR2 antagonists for treatment of CCR2 -mediated inflammatory syndromes and disorders. WO2008109238; 2008
19. Xia M, Hou C, DeMong DE, et al. Synthesis, structure-activity relationship and in vivo antiinflammatory efficacy of substituted dipiperidines as CCR2 antagonists. J Med Chem 2007;50:5561-5563 (Pubitemid 350106010)
20. Buntinx M, Hermans B, Goossens J, et al. Pharmacological profile of JNJ-27141491 [(S)-3-[(3,4-difluorophenyl)propyl]-5-isoxazol-5-yl-2-thioxo-2,3- dihydro-1Himidazole- 4-carboxyl acid methyl ester], as a noncompetitive and orally active antagonist of the human chemokine receptor CCR2. J Pharmacol Exp Ther 2008;327:1-9
21. Incyte. Preparation of 3-cycloalkylaminopyrrolidine chemokine receptor antagonists as antiinflammatory and immunomodulatory bioactive compounds. WO2005060665; 2005
22. Pfizer. Preparation of piperidinyl and piperazinyl 3- aminocyclopentanecarboxamides as modulators of chemokine receptors. US2006004018; 2006
23. Brodmerkel C, Huber R, Covington M, et al. Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J Immunol 2005;175:5370-5378 (Pubitemid 41456423)
24. Carter PH, Brown GD, Friedrich SR, et al. Capped diaminopropionamide- glycine dipeptides are inhibitors of CC chemokine receptor 2 (CCR2 ). Bioorg Med Chem Lett 2007;17:5455-5461 (Pubitemid 47391266)
25. Cherney RJ, Mo R, Meyer DT, et al. Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists. J Med Chem 2008;51:721-724 (Pubitemid 351304681)
26. Bristol-Myers Squibb. Preparation of pyrrolidin-2-one derivatives as chemokine receptor modulators. WO2008014360; 2008
27. Novartis. Preparation of 1H-indole-2- carboxylic acid N-(piperidin-4-yl)amides and related derivatives as chemokine receptor, particularly CCR2 and CCR5 antagonists. WO2005077932; 2005
28. Novartis. Preparation of N-piperidinylethylcyclohexyl indolecarboxamide derivatives as inhibitors of chemokine receptors or macrophage protein. WO2008101905; 2008
29. ChemoCentryx. Preparation of aryl and heteroaryl sulfonamides as CCR2 antagonists. WO2006076644; 2006
30. ChemoCentryx. Preparation of N-phenylbenzenesulfonamide derivatives as CCR2 inhibitors. WO2008008374; 2008
31. ChemoCentryx. N-(Triazolylpyridinyl)-benzenesulfonamides as chemokine receptor antagonists, their preparation, pharmaceutical compositions, and use in therapy. WO2008008375; 2008
32. Glaxo. Preparation of pyridinyl sulfonamide modulators of chemokine receptors. WO 2007067875; 2007
33. Glaxo. Preparation of benzenesulfonamide inhibitors of CCR2 chemokine receptor. WO 2007014008; 2007
34. Glaxo. Preparation of azolylmethylbenzenesulfonamides as CCR2 chemokine receptor antagonists. WO2007014054; 2007
35. Angelini. Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition. WO2008061671; 2008
36. Millennium. Preparation of pyrrolidinylazepans and pyrrolidinyloxepanes as antagonists of CCR2 chemokine receptors. WO2007053495; 2007
37. Millennium. Preparation of bipyrrolidine and thienylpyrrolidine derivatives as antagonists of CCR2. WO2007053499; 2007
38. Millennium. Preparation of pyrrolidinylpiperidines and related compounds as antagonists of chemokine CCR2 inhibitors. WO2007053498; 2007
39. Abbott. Aminopyrrolidine derivatives as chemokine receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of autoimmune diseases. WO2008060621; 2008
40. Astrazeneca AB. Piperazine derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as antagonists of CC chemokines (CCR2b and CCR5) for the treatment of inflammatory diseases. WO2007071952; 2007
41. Epix. Preparation of benzothiadiazine compounds and their use as chemokine receptor antagonists. WO2008045558; 2008
42. Epix. Preparation of piperidinyl and pyrrolidinyl carboxamide compounds as chemokine receptor antagonists for treating diseases associated with monocyte, leukocyte, and lymphocyte accumulation. WO2008045564; 2008